Equities Analysts Set Expectations for Labcorp Q2 Earnings

Labcorp Holdings Inc. (NYSE:LH - Free Report) - Equities researchers at Leerink Partnrs increased their Q2 2025 EPS estimates for Labcorp in a report issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now expects that the medical research company will post earnings of $4.16 per share for the quarter, up from their prior estimate of $4.14. The consensus estimate for Labcorp's current full-year earnings is $16.01 per share. Leerink Partnrs also issued estimates for Labcorp's Q3 2025 earnings at $4.09 EPS, Q4 2025 earnings at $4.04 EPS, FY2026 earnings at $17.73 EPS and FY2028 earnings at $22.30 EPS.

Labcorp (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical research company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.73 by $0.11. The business had revenue of $3.35 billion for the quarter, compared to analyst estimates of $3.41 billion. Labcorp had a net margin of 5.55% and a return on equity of 15.27%. Labcorp's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.68 earnings per share.

LH has been the subject of a number of other research reports. Redburn Atlantic started coverage on shares of Labcorp in a research report on Wednesday, April 2nd. They set a "buy" rating and a $276.00 target price for the company. Piper Sandler reissued a "neutral" rating and set a $280.00 target price (up previously from $260.00) on shares of Labcorp in a research report on Tuesday, May 6th. Robert W. Baird lifted their price objective on shares of Labcorp from $253.00 to $267.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 30th. Truist Financial lifted their price objective on shares of Labcorp from $274.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, May 12th. Finally, Morgan Stanley lifted their target price on shares of Labcorp from $270.00 to $283.00 and gave the company an "overweight" rating in a report on Wednesday, June 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $276.08.

Labcorp Stock Down 0.1%

Shares of LH stock opened at $257.68 on Wednesday. Labcorp has a 12 month low of $198.96 and a 12 month high of $265.72. The stock has a market cap of $21.57 billion, a P/E ratio of 29.79, a P/E/G ratio of 1.63 and a beta of 0.82. The company has a current ratio of 1.84, a quick ratio of 1.60 and a debt-to-equity ratio of 0.68. The company has a 50 day simple moving average of $253.01 and a two-hundred day simple moving average of $242.66.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th were issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.12%. Labcorp's dividend payout ratio is presently 33.29%.

Insider Buying and Selling

In related news, Director Kerrii B. Anderson sold 500 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $265.00, for a total transaction of $132,500.00. Following the sale, the director directly owned 12,166 shares of the company's stock, valued at approximately $3,223,990. This represents a 3.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 1,900 shares of the firm's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $238.36, for a total value of $452,884.00. Following the transaction, the executive vice president directly owned 2,244 shares of the company's stock, valued at $534,879.84. This represents a 45.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,834 shares of company stock worth $2,928,714 over the last 90 days. 0.84% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Labcorp

Several hedge funds have recently bought and sold shares of the business. MassMutual Private Wealth & Trust FSB raised its stake in shares of Labcorp by 10.2% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 433 shares of the medical research company's stock valued at $114,000 after acquiring an additional 40 shares in the last quarter. Everpar Advisors LLC grew its holdings in shares of Labcorp by 12.9% during the 2nd quarter. Everpar Advisors LLC now owns 1,207 shares of the medical research company's stock worth $317,000 after purchasing an additional 138 shares in the last quarter. Parallel Advisors LLC boosted its stake in Labcorp by 15.3% in the 2nd quarter. Parallel Advisors LLC now owns 3,419 shares of the medical research company's stock valued at $898,000 after buying an additional 453 shares in the last quarter. Fox Hill Wealth Management acquired a new stake in Labcorp in the 2nd quarter valued at $208,000. Finally, Somerset Trust Co acquired a new position in Labcorp in the second quarter worth $211,000. 95.94% of the stock is owned by hedge funds and other institutional investors.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.